A randomized non-comparative phase II study of maintenance t...

A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM D17-01 PRODIGE 63 STUDY)

ANNÉE

2021

AUTEURS

Hilmi M, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D, Neuzillet C,

CONGRÈS/REVUE

ESMO

ÉTUDE

PRODIGE 63-GERCOR-TEDOPAM

Localisation

Cancer du Pancréas

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/a-randomized-non-comparative-phase-ii-study-of-maintenance-therapy-with-folfiri-alone-or-in-combination-with-tedopi-vaccine-after-induction-therapy